Armata Pharmaceuticals, Inc. 8-K

What Happened

• On June 23, 2026, Armata Pharmaceuticals, Inc. (ARMP) announced in a press release (attached as Exhibit 99.1 to a Form 8-K) that it received $2.5 million of additional non-dilutive award funding from the U.S. Department of Defense. The funding is designated to support development of AP-SA02, Armata’s intravenously administered Staphylococcus aureus phage product candidate for complicated bacteremia infections.

Key Details

• Date of announcement: June 23, 2026 (press release filed on Form 8-K, Item 8.01).
• Amount: $2.5 million in additional award funding.
• Funder: U.S. Department of Defense (DoD).
• Purpose: Development of AP-SA02, an IV-administered S. aureus bacteremia phage candidate; funding is described as non-dilutive.

Why It Matters

• This award provides $2.5M of targeted, non-dilutive funding specifically for AP-SA02 development, meaning the funding does not require issuing new equity to investors.
• The filing documents continued DoD support for Armata’s S. aureus phage program and is material information investors can use to assess the company’s program funding sources and development progress.